Up to 20% of all coronary angiograms reveal coronary chronic total occlusions (CTOs). The lack of robust type A evidence with hard clinical outcomes on the benefits of CTO revascularization has hampered attempts to develop recommendations regarding the optimal management of CTOs. This review presents issues surrounding CTO revascularization within the framework of the appropriate use criteria ratings. Appropriate use criteria ratings downgrade CTO percutaneous coronary intervention revascularization relative to non-CTOs and to surgical revascularization. Specific aspects of CTO revascularization include ischemic burden, impact of revascularization on quality of life, risks in CTO revascularization, and the importance of complete revascularization. Contemporary data suggest CTO revascularization may have substantial impact on patient outcomes; thus, revascularization should likely be held to similar criteria as nonocclusive 
its expected risks by a sufficiently wide margin (7). The AUC classifies patients on the basis of symptom severity, findings on pre-procedural stress testing, and anatomic location and extent of coronary stenosis. The only modifier of coronary anatomy included in the current AUC is the lesion being a CTO; other forms of anatomic complexity are not considered. The implicit assumption is that for the same lesion location, symptom severity, and ischemic burden, a CTO differs from a non-CTO, either due to the perceived benefit of revascularization or the harm of the procedure. We will examine this rationale in detail.
There are 2 broad clinical revascularization scenarios involving CTOs: isolated CTOs or multivessel disease.
ISOLATED ("LONE") CTO
Clinical indications 23 to 27 specifically approach single-vessel CTOs, making different recommendations for CTO and nonocclusive lesions (Central Illustration) for the same symptom severity, lesion location, extent of ischemia, and intensity of medications (7). In several scenarios, CTO revascularization is downgraded compared with non-CTO vessels ("uncertain" in CTO from "appropriate" in non-CTO, and "inappropriate" in CTO from "uncertain" in non-CTO), supporting a more conservative approach to revascularization of CTOs relative to non-CTOs.
The document does not clearly state why CTO revascularization was discouraged. However, the conceptual framework presented earlier suggests that the rationale is the elevated risk due to the procedure's complexity, balanced against their uncertain benefits. (24) . Although coronary perforation is a serious PCI complication, occurring more frequently in CTO than in non-CTO PCI procedures, it is relatively rare and generally requires no specific intervention or need for bypass surgery (25) . CR VERSUS IR. CR may be defined on the basis of anatomy, extent of ischemia, and other criteria (27) .
The most accepted definition is simply successful treatment of all major epicardial coronary vessels by a revascularization modality, either bypass surgery or percutaneous revascularization (27) . A summary of studies and registries comparing CR and IR can be found in Table 2 . was <75%, with no effect with higher extent of infarction (52) . These beneficial effects were observed up to 3 years after recanalization (53, 54) . No data specifically address the relationship between viability and clinical outcomes in CTO patients; however, several small observational studies and 2 randomized trials addressed this question (55) (56) (57) (58) . In a study of The AUC differentiates the revascularization modality for CTOs in the setting of multivessel disease, with an AUC rating of "appropriate" for surgical revascularization and "uncertain" for PCI (and, in LM þ 3-vessel disease, "appropriate" for CABG and "inappropriate"
for PCI) (7). This reflects the fact that successful PCI performance in CTO is difficult for most PCI physicians. However, procedural success and safety highly depend upon the operator's experience; thus, this rating should be interpreted in the context of whether a CTO expert performed the procedure.
THE FUTURE OF CTO REVASCULARIZATION
Many studies and several meta-analyses compared 
CONCLUSIONS
The therapeutic nihilism often associated with revascularization in CTO has been plagued by misconceptions as to the degree of symptoms and ischemia caused, and the potential benefit of revas- 
